Mono Pharmacare schedules EGM to appoint auditor and independent director

mono pharmacare Limited will convene an Extraordinary General Meeting (EGM) on June 30, 2026, to seek shareholder approval for the appointment of a statutory auditor and an independent director. The meeting is scheduled to commence at 11:00 A.M. IST via physical and video conferencing modes at the company's registered office in Ahmedabad.

The board proposes appointing M/s. R K Mergu & Co., Chartered Accountants (Firm Registration No. 136876W), to fill a casual vacancy created by the resignation of M/s. Kumbhat & Co. LLP. The new auditors will hold office until the conclusion of the ensuing Annual General Meeting and conduct the statutory audit for the financial year 2025-26.

Additionally, the company seeks to regularize the appointment of Ms. Nirmala Ranawat (DIN: 11309088) as an independent director. She was initially appointed as an additional director on June 3, 2026. If approved, she will hold office for a term of five consecutive years.

Shareholders can participate in the decision-making process through remote e-voting, which will be facilitated by CDSL. The e-voting period opens on June 27, 2026, at 11:00 A.M. and closes on June 29, 2026, at 5:00 P.M. The record date for determining eligibility is June 23, 2026.

Key Resolutions

Item	Agenda	Details
1	Appointment of Statutory Auditor	M/s. R K Mergu & Co. to fill casual vacancy till the next AGM.
2	Appointment of Independent Director	Ms. Nirmala Ranawat for a term of 5 years.

Ms. Nirmala Ranawat is a Practicing Company Secretary with qualifications including FCS (ICSI), M.Com., CA-IPCC, and LL.B. She currently serves as a director in Goversphere India Private Limited and Wise Monkey Advisory Private Limited. She holds no shares in Mono Pharmacare Limited and is not related to any of the company's directors or key managerial personnel.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
0.0%	-6.01%	-7.98%	-33.64%	-52.80%	-64.04%

Mono Pharmacare Limited has confirmed full compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, regarding the maintenance of a Structured Digital Database (SDD) for the financial year ended March 31, 2026. The certification, filed on May 30, 2026, verifies that the pharmaceutical company successfully captured all required Unpublished Price Sensitive Information (UPSI) events during the period, ensuring robust internal controls and data integrity.

The compliance certificate, issued by Mrs. Ankita Surana of Surana And Kothari Associates LLP, attests that mono pharmacare maintained a secure, non-tamperable system with restricted access. The database is designed to preserve records for eight years and includes a comprehensive audit trail to monitor access and modifications. This infrastructure is critical for preventing insider trading and ensuring transparency in information dissemination.

During the period from April 1, 2025, to March 31, 2026, the company was required to capture seven specific events within the SDD. The certification confirms that all seven events were successfully recorded, with no instances of non-compliance identified. The system captured the nature of the UPSI along with precise date and time stamps, fulfilling the regulatory mandates set forth under Regulation 3(5) and 3(6) of the PIT Regulations.

Key Compliance Metrics for FY26

Metric	Status
UPSI Events Required	7
UPSI Events Captured	7
Non-Compliances Reported	Nil
Record Retention Period	8 years
Database Security	Non-tamperable with access controls

The filing was submitted to the National Stock Exchange of India Limited by Panilam Lakhatariya, Managing Director of Mono Pharmacare Limited. The statutory confirmation provided by the practising company secretary underscores the company's adherence to governance standards and its commitment to maintaining a fair and transparent securities market environment.